CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
Methotrexate (MTX)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01737944
NCT01737944Phase 2Completed

Exposure, Safety and Local Tolerance Study Comparing 3 Routes of Methotrexate (MTX) Administration: Vibex-MTX Device, Subcutaneous (SC)and Intramuscular (IM) in Adult Subjects With Rheumatoid Arthritis

Antares Pharma Inc.·interventional·Posted Nov 30, 2012·Updated Feb 25, 2014

In Brief

A Phase 2 clinical trial evaluating Methotrexate (MTX) for Rheumatoid Arthritis. Completed, enrolled 38 participants across 1 site.

Detailed Summary

Pharmacokinetics (PK) study

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 30, 2012
Enrollment StartJan 1, 2011
Primary CompletionMay 1, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.6 years ago

Interventions

Methotrexate (MTX)drug

Vibex MTX Device